The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 studyMikkel Rosendahl, Michael Andersson, Johan Ahlgren et al.|European Journal of Cancer|2009Cited by 21
Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?Thomas Lindahl, Jonas Bergh, Johan Ahlgren et al.|Acta Oncologica|2000Cited by 17
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Carl Blomqvist, Johan Ahlgren et al.|Acta Oncologica|2011Cited by 11
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancerHenrik Lindman, Jonas Bergh, Gunnar Åström et al.|Acta Oncologica|2006Cited by 8
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)Henrik Lindman, Carl Blomqvist, Michael Andersson et al.|European Journal of Cancer|2018Cited by 4